Prognosis and Diagnosis of Acute Gastrointestinal Dysfunction in Cardiac Surgery Patients
PREDICT-GICS
1 other identifier
interventional
100
1 country
1
Brief Summary
The purpose of this prospective observational clinical cohort study is to develop a scientifically based approach to the prediction and early diagnosis of intestinal dysfunction in cardiac surgery patients. The main questions that the study should answer: What are the main risk factors for the development of intestinal dysfunction? What specific and non-specific biomarkers can predict the development of intestinal dysfunction? The study participants will be monitored from the moment of hospitalization until the end of their stay in a medical facility
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 6, 2026
CompletedFirst Posted
Study publicly available on registry
February 19, 2026
CompletedStudy Start
First participant enrolled
March 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2028
February 19, 2026
February 1, 2026
2.5 years
February 6, 2026
February 18, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Identification of markers of intestinal dysfunction:
Intra-abdominal hypertension of 2 or more degrees and/or gastrostasis (stomach volume \>1.5ml / kg body weight measured no earlier than 4 hours after the last meal); Abdominal compartment syndrome
During the first 24h after surgery for all patients. On the third, sixth and ninth day, if the patient stay in the ICU
The use of pharmacological stimulation of gastrointestinal motility
During the first 24h after surgery for all patients. On the third, sixth and ninth day, if the patient stay in the ICU
Secondary Outcomes (6)
Hospital mortality
During the first 24h after surgery for all patients. On the third, sixth and ninth day, if the patient stay in the ICU
Number of days spent in the ICU
During the first 24h after surgery for all patients. On the third, sixth and ninth day, if the patient stay in the ICU
Total duration of vasopressor support
During the first 24h after surgery for all patients. On the third, sixth and ninth day, if the patient stay in the ICU
The dynamics of the severity of the course on the scale of sequential organ dysfunction (SOFA/SOFA-2) in patients with intestinal dysfunction in the framework of multiorgan dysfunction;
During the first 24h after surgery for all patients. On the third, sixth and ninth day, if the patient stay in the ICU
Total duration of mechanical lung ventilation
During the first 24h after surgery for all patients. On the third, sixth and ninth day, if the patient stay in the ICU
- +1 more secondary outcomes
Study Arms (4)
non-complicated patients
EXPERIMENTALpatients without any complications after cardiac surgery
complicated patients
EXPERIMENTALpatients with any complications, but without gastrointestinal dysfunction after cardiac surgery
gastrointestinal dysfunction
EXPERIMENTALpatients with gastrointestinal dysfunction after cardiac surgery
gastrointestinal dysfunction and MODS
EXPERIMENTALpatients with gastrointestinal dysfunction and MODS after cardiac surgery
Interventions
additional blood testing for specific and non-specific markers of intestinal dysfunction, ultrasound examination of abdominal organs and measurement of intra-abdominal pressure
Eligibility Criteria
You may qualify if:
- Surgery on the heart and main vessels with a high risk of developing gastrointestinal dysfunction (according to literature data and our own retrospective study);
- Patient's consent to participate in the study
You may not qualify if:
- Patient's refusal to participate in the study;
- HIV infection in the patient;
- Immunosuppressive therapy;
- Oncological disease;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Petrovsky National Research Centre of Surgery
Moscow, Russia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 6, 2026
First Posted
February 19, 2026
Study Start
March 10, 2026
Primary Completion (Estimated)
September 1, 2028
Study Completion (Estimated)
September 30, 2028
Last Updated
February 19, 2026
Record last verified: 2026-02